Drugs / GSK2282512A
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01711736 | Nov 2012 → Feb 2013 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01196975 | Oct 2010 → Jan 2011 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01198756 | Oct 2010 → Jul 2011 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2282512A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01711736 ↗ |
| Known as | FLU-Q-QIV | “The purpose of this study is to investigate the immunogenicity, reactogenicity and safety of the new influenza vaccine GSK2282512A (FLU-Q-QIV) and compare its activity to the...” NCT01711736 ↗ |
| Modality | Vaccine | “one dose of the GSK2282512A vaccine” NCT01196975 ↗ |
| Route | Intramuscular | “The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.” NCT01196975 ↗ |